July 26th 2023
Closing out their panel on metastatic colorectal cancer, expert oncologists consider ongoing challenges and future evolutions within the treatment landscape.
July 19th 2023
Focused discussion on clinical trial data with trastuzumab deruxtecan in the setting of HER2+ metastatic colorectal cancer.
A panel of oncologists shares comprehensive insight to clinical trial data with tucatinib in patients with HER2+ metastatic colorectal cancer.
July 12th 2023
Switching their focus to HER2+ metastatic colorectal cancer, panelists discuss best practices in testing HER2 to aid in the timely selection of best available therapies.
Expert perspectives on novel combination and immunotherapy strategies within BRAF-mutated metastatic colorectal cancer management.
July 5th 2023
Shared insight to the importance of tumor sidedness and its impact on the selection of EGFR-targeted therapy in metastatic colorectal cancer.
Key opinion leaders in metastatic colorectal cancer management review data from the BREAKWATER study in BRAF-V600E–mutated disease.
June 28th 2023
Centering discussion on patients with BRAF-V600E mutations in metastatic colorectal cancer, panelists reflect on the treatment armamentarium in this setting.
A brief review of how circulating tumor DNA testing has impacted the real-world management of patients with metastatic colorectal cancer.
June 21st 2023
A focused discussion on the respective roles of circulating tumor DNA and minimal residual disease testing in the management of patients with nonmetastatic colorectal cancer.
Expert panelists provide their perspective on the current state of molecular testing in metastatic colorectal cancer and how it impacts treatment pathways.
October 1st 2021
Takeaways from a discussion on treatment advances in hepatocellular carcinoma.
Professionals who treat patients with hepatocellular carcinoma comment on the need for more research and biomarkers to fuel treatment decisions.
September 24th 2021
An overview of the second-line treatment landscape for patients with advanced hepatocellular carcinoma and considerations regarding the sequencing of novel therapies.
Thoughts regarding the COSMIC-312 study of cabozantinib plus atezolizumab as frontline therapy for advanced hepatocellular carcinoma.
September 17th 2021
A debate regarding the appropriateness of immunotherapy following liver transplantation in patients with hepatocellular carcinoma.
Implications on treatment practices of the LEGACY study of Y-90 glass microspheres in patients with unresectable solitary hepatocellular carcinoma.
September 10th 2021
An overview of factors that deem patients appropriate for atezolizumab/bevacizumab vs lenvatinib or sorafenib as frontline therapy for advanced hepatocellular carcinoma.
Considerations regarding the use of nivolumab as frontline treatment for advanced hepatocellular carcinoma.
September 3rd 2021
Exciting developments using novel therapies as systemic treatment for advanced hepatocellular carcinoma.